All Oncology articles
-
Opinion‘Molecular glues’ are sticking it to cancer
Compounds that enhance selected protein–protein interactions to interfere with signalling or send proteins to be destroyed are making it possible to influence processes that were previously considered ‘undruggable’
-
BusinessProtein degrading breast cancer drugs navigate bumpy road to market
Camizestrant is now approved in US, UK and Europe despite uncertainty over long-term benefit, while vepdegestrant is approved in the US
-
BusinessNovartis cutting up to 8000 jobs
Restructure splits commercial activities geographically instead of by treatment area
-
BusinessBayer forms cancer-drug partnership with Loxo
Alliance could see Loxo net up to $1.55bn in upfront and milestone payments
-
BusinessIpsen to buy Merrimack’s cancer drugs
$1bn deal covers two liposome-encapsulated formulations of approved therapies
-
BusinessTakeda to buy cancer specialist Ariad
Japan’s largest drug company agrees $5.2bn deal to expand oncology portfolio and boost pipeline
-
PodcastPARP: Poly (ADP-ribose) polymerase
Kat Arney explains how a protein that repairs broken DNA holds the key to killing cancer cells – but only if you stop it from doing its job